泊马度胺临床用药中国专家共识(2022年版)

Chinese expert consensus on the clinical use of pomalidomide(2022 version)

泊马度胺是第3代免疫调节剂,多项临床研究显示含泊马度胺的联合方案治疗复发难治多发性骨髓瘤具有良好的效果,可改善患者预后。2013年美国食品药品管理局(FDA)批准泊马度胺用于治疗复发难治多发性骨髓瘤,2020年5月又批准其用于治疗艾滋病相关卡波西肉瘤。泊马度胺于2020年11月在我国获批上市。鉴于目前我国多数临床医师对于泊马度胺用药经验尚少,共识专家组成员参考国内外相关研究进展及临床实践,制定了泊马度胺临床用药中国专家共识,旨在为我国临床医师用药提供参考。

Pomalidomide is a third-generation immunomodulatory drug.Several clinical studies have shown that the combined regimen containing pomalidomide has good efficacy in the treatment of relapsed/refractory multiple myeloma.In 2013,pomalidomide was approved by the Food and Drug Administration(FDA)of the United States for the treatment of relapsed/refractory multiple myeloma;later in May 2020,the FDA approved it for the treatment of AIDS-related Kaposi sarcoma.Pomalidomide was approved for marketing in China in November 2020,and most clinicians in China have little experience in the use of pomalidomide.By referring to relevant researches at home and abroad and combining with clinical practice,the members of the consensus expert group formulated the Chinese expert consensus on the clinical use of pomalidomide,in order to provide a reference for Chinese clinicians.